Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
American Academy of Pediatrics. Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.
Pediatrics, 106 (2000), pp. 362-366
[3.]
R. Dagan, R. Melamed, O. Zamir, O. Leroy.
Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B,14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their booster ability by native polysaccharide antigens.
Pediatr Infect Dis J, 16 (1997), pp. 1053-1059
[4.]
H.R. Shinefield, S. Black, P. Ray, I. Chang, N. Lewis, B. Fireman, et al.
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Pediatr Infect Dis J, 18 (1999), pp. 757-763
[5.]
S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J.R. Hansen, et al.
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.
Pediatr Infect Dis J, 19 (2000), pp. 187-195
Copyright © 2002. Asociación Española de Pediatría
